Q-omics provides the consensus-scored KRT8P25 profile across patient tissues and cancer cell-line models. KRT8P25 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT8P25 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, KRT8P25 RNA expression shows 5,400 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where KRT8P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P25 survival associations across molecular data types. KRT8P25 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P25 RNA expression–survival associations across cancer types. High KRT8P25 expression shows unfavorable associations in SKCM, LGG, ESCA, ACC and UCEC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .020). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT8P25 RNA expression.
This table summarizes KRT8P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P25 shows lower tumor expression in THCA and higher tumor expression in BRCA, LUAD, PRAD, KIRC and KICH. The BRCA box plot shows higher KRT8P25 RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p < 0.001).
This table shows molecular features associated with KRT8P25 in patient tissues and cancer cell lines. In patient samples, KRT8P25 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
